Fig. 6: AAV-mediated overexpression of Srxn1 protects against AP. | Cell Death & Disease

Fig. 6: AAV-mediated overexpression of Srxn1 protects against AP.

From: Sulfiredoxin-1 attenuates injury and inflammation in acute pancreatitis through the ROS/ER stress/Cathepsin B axis

Fig. 6

A Schematic of the microinfusion system for intraductal administration of AAV. B Fluorescence imaging of pancreas (upper) and pancreatic sections (lower) after AAV administration for 14 days. C SRXN1 RNA and protein was upregulated by AAV-Srxn1 in pancreatic tissues. D AAV-Srxn1 markedly reduced amylase and lipase activity in plasma compared with control. F Cleaved caspase 3 was decreased in AAV-Srxn1 group. G IHC and IF staining of CD68 and Ly6G showed a reduced infiltration of M1 macrophages and neutrophils by AAV-Srxn1 in pancreas. H Flow cytometry analysis of blood showed a decrease of neutrophils (CD45+/CD11b+/Ly6G+) in AAV-Srxn1 group. I Flow cytometry analysis of pancreatic tissues showed a decrease of infiltrating neutrophils (CD45+/CD11b+/Ly6C+/Ly6G+) and macrophages (CD45+/CD11b+/F4/80+) in AAV-Srxn1 group. J AAV-Srxn1 decreased the expression of p-PERK, XBP1s, and the active form of CSTB in the pancreas. **p < 0.01, ***p < 0.001. n = 5.

Back to article page